EUCTR2012-001729-28-GB进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Multi-Dose, Cross-Over, Efficacy and Safety Study of IPI-145 in Mild Asthmatic Subjects Undergoing Allergen Challenge - Not Applicable
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female adults between 18 and 60 years of age
- •2. Body Mass Index (BMI) between 18 and 32 kg/m² at Screening
- •3. Written informed consent obtained from the subject prior to any study Screening procedures
- •4. Previously documented diagnosis of asthma for at least 6 months prior to Screening or a history of at least 6 months of episodic symptoms of airflow obstruction such as wheezing and/or chest tightness with other significant lung diseases ruled out (e.g., chronic obstructive pulmonary disease [COPD])
- •5. Forced expiratory volume in one second (FEV1) =70% of predicted value at Screening (based on American Thoracic Society [ATS]/ European Respiratory Society [ERS] standards
- •6. A positive skin prick test to test allergen [defined as the indurations of skin test wheal =2 mm larger in diameter than diameter of control wheal
- •7. Early-phase asthmatic response (EAR) of at least 20% and a late-phase asthmatic response (LAR) of as at least 15% to inhaled allergen challenge [response defined as a decrease from pre-challenge in FEV1 on 2 consecutive occasions within 0 to <3 hours of last allergen challenge administered for EAR and within 3 to 10 hours for LAR]
- •8. a. Sexually active women, unless surgically sterile (confirmed by documentation) or at least 2 year post-menopausal (confirmed by FSH blood level at Screening), must have a negative serum pregnancy test result at Screening and agree to use two effective methods of contraception from the signing of informed consent through 21 days after the last dose of study drug
- •b. Sexually active men, unless surgically sterile, must agree to use an effective method of birth control from the signing of informed consent through 21 days after the last dose of study drug
- •9. Subject has the willingness and ability to complete all the study requirements, instructions, or study related restrictions through the final Safety Follow-up Phone Screen 21 days after last dose of study drug
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any prior treatment with a phosphoinositide-3-kinase (PI3K) inhibitor in a previous clinical study
- •2. History of allergy or reaction to any component of the study drug formulation, such as excipients in the study drug capsule or oral solution (See Section 7.1)
- •3. Acute asthma exacerbations leading to hospitalization, emergency room visit, or unscheduled health care provider visit, within 6 weeks prior to Screening or any previous history of intubation or admission to an intensive care unit for asthma
- •4. Use of any medication for the treatment of asthma other than a short-acting ß2 agonist (as needed) within the 4 weeks prior to Screening and no significant changes in short-acting ß2 agonist use over the 6 weeks prior to Screening
- •5. Use if anti-IgE therapy (omalizumab) within 12 weeks prior to Screening
- •6. Upper or lower respiratory tract infections or acute illnesses or evidence of on-going clinically significant infection within the 4 weeks prior to Screening
- •7. If undergoing concomitant allergy vaccination therapy (desensitization immunotherapy), <3 months of stable maintenance doses prior to the Baseline allergen challenge; any allergy concomitant vaccination therapy leading to desensitization to any of the allergens used in the allergen challenge
- •8. Participation in another clinical study within 90 days prior to study Screening or until completion of the final Safety Follow-up Visit
- •9. Blood donation (=500 mL) within 3 months before Screening
- •10. Any history of treatment with a leukocyte-depleting agent (eg, rituximab, alemtuzumab)
- •11. Positive laboratory test result for hepatitis B or C or HIV-1 or HIV-2 at Screening
- •12. A positive screen result for active or latent tuberculosis (verified by either PPD skin test or Quantiferon blood test at Screening)
- •13. History of significant systemic disease (e.g., cancer, coronary artery disease, seizure disorder) as judged by the Investigator
- •14. Currently pregnant or lactating
- •15. Smoking within 6 months prior to Screening or a smoking history of =10 pack-years
- •16. A positive screen for drug and/or alcohol abuse at Screening or reported use of illegal drugs or history of abuse of prescription drugs or alcohol within 1 year before Screening
- •17. Planned elective surgery from the time of Screening through the final Safety Follow-up Visit
- •18. Clinically significant abnormalities on safety laboratory tests, 12-lead ECG, vital signs, or physical examination at Screening, based on the medical judgment of the Investigator
- •19. Vulnerable subjects (i.e., those subjects imprisoned or lawfully kept in an institution)
- •20. Subject is an employee or direct relative of an employee of the contract research organization (CRO) or Infinity Pharmaceuticals Inc.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectioCrohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-000886-19-ATMillennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)96
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer PaiEUCTR2005-001725-28-ATGlaxoSmithKline R & D Limited750
进行中（未招募）
1 期
An efficacy and safety study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness.Myasthenia GravisEUCTR2018-002132-25-NLargenx BVBA150
进行中（未招募）
1 期
A Phase 2b study to demonstrate the safety and efficacy of Tildrakizumab in patients with Active Psoriatic ArthritisMedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000018188Psoriatic ArthritisEUCTR2016-003937-62-HUSUN Pharma Global FZE360
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes MellitusMedDRA version: 14.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2012-002414-39-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.4,202